Literature DB >> 22911633

Deficiency of G-protein-coupled bile acid receptor Gpbar1 (TGR5) enhances chemically induced liver carcinogenesis.

Wei-Dong Chen1, Donna Yu, Barry M Forman, Wendong Huang, Yan-Dong Wang.   

Abstract

UNLABELLED: Gpbar1 (TGR5), a membrane-bound bile acid receptor, is well known for its roles in regulation of energy homeostasis and glucose metabolism. TGR5 activation also inhibits nuclear factor κB (NF-κB)-mediated inflammation. Here we show that TGR5 deficiency enhances chemically induced liver carcinogenesis, and that TGR5 is a negative regulator of signal transducer and activator of transcription 3 (STAT3) signaling. Mice lacking TGR5 were much more susceptible to diethylnitrosamine (DEN)-induced acute liver injury and liver carcinogenesis than wildtype (WT) mice. Consistent with the increasing incidence of liver cancer in TGR5(-/-) mice, hepatocyte death, compensatory proliferation, and gene expression of certain inflammatory cytokines and matrix metalloproteinases were more sensitive to DEN induction in the absence of TGR5 signaling. In vitro, TGR5 activation greatly inhibited proliferation and migration of human liver cancer cells. We then found that TGR5 activation strongly suppressed STAT3 signaling in vitro and in vivo. Furthermore, we observed that TGR5 antagonizes the STAT3 pathway through suppressing STAT3 phosphorylation, its transcription activity, and DNA binding activity, which suggests that TGR5 antagonizes liver tumorigenesis at least in part by inhibiting STAT3 signaling.
CONCLUSION: These findings identify TGR5 as a novel liver tumor suppressor that may serve as an attractive therapeutic tool for human liver cancer.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22911633      PMCID: PMC3745510          DOI: 10.1002/hep.26019

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  45 in total

1.  Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.

Authors:  Carlo Schneider; Andreas Teufel; Tetyana Yevsa; Frank Staib; Anja Hohmeyer; Gudrun Walenda; Henning W Zimmermann; Mihael Vucur; Sebastian Huss; Nikolaus Gassler; Hermann E Wasmuth; Sergio A Lira; Lars Zender; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  Gut       Date:  2012-01-20       Impact factor: 23.059

Review 2.  Molecularly targeted therapy in hepatocellular carcinoma.

Authors:  Hung Huynh
Journal:  Biochem Pharmacol       Date:  2010-04-04       Impact factor: 5.858

3.  Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.

Authors:  Guobin He; Guann-Yi Yu; Vladislav Temkin; Hisanobu Ogata; Christian Kuntzen; Toshiharu Sakurai; Wolfgang Sieghart; Markus Peck-Radosavljevic; Hyam L Leffert; Michael Karin
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

Review 4.  STAT3: a target to enhance antitumor immune response.

Authors:  Heehyoung Lee; Sumanta Kumar Pal; Karen Reckamp; Robert A Figlin; Hua Yu
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

5.  Inflammatory and catabolic signalling in intervertebral discs: the roles of NF-κB and MAP kinases.

Authors:  Karin Wuertz; Nam Vo; Dimitris Kletsas; Norbert Boos
Journal:  Eur Cell Mater       Date:  2012-02-16       Impact factor: 3.942

Review 6.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

7.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

8.  Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Meihua Wang; Donna Yu; Barry M Forman; Wendong Huang
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

Review 9.  Nuclear factor-kappa B and cancer: its role in prevention and therapy.

Authors:  Alok C Bharti; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

10.  TGR5-mediated bile acid sensing controls glucose homeostasis.

Authors:  Charles Thomas; Antimo Gioiello; Lilia Noriega; Axelle Strehle; Julien Oury; Giovanni Rizzo; Antonio Macchiarulo; Hiroyasu Yamamoto; Chikage Mataki; Mark Pruzanski; Roberto Pellicciari; Johan Auwerx; Kristina Schoonjans
Journal:  Cell Metab       Date:  2009-09       Impact factor: 27.287

View more
  18 in total

1.  Retraction statement: The deficiency of G-protein-coupled bile acid receptor Gpbar1 (TGR5) enhances chemically-induced liver carcinogenesis.

Authors: 
Journal:  Hepatology       Date:  2013-09       Impact factor: 17.425

2.  22nd European Congress on Obesity (ECO2015), Prague, Czech Republic, May 6-9, 2015: Abstracts.

Authors: 
Journal:  Obes Facts       Date:  2015-04-30       Impact factor: 3.942

Review 3.  Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.

Authors:  Jessica Tsuei; Thinh Chau; David Mills; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2014-06-20

Review 4.  The bile acid TGR5 membrane receptor: from basic research to clinical application.

Authors:  Henri Duboc; Yvette Taché; Alan F Hofmann
Journal:  Dig Liver Dis       Date:  2014-01-09       Impact factor: 4.088

Review 5.  Primary biliary cholangitis: new treatments for an old disease.

Authors:  Hirsh D Trivedi; Blanca Lizaola; Elliot B Tapper; Alan Bonder
Journal:  Frontline Gastroenterol       Date:  2016-11-03

Review 6.  Advances in pharmacotherapy for primary biliary cirrhosis.

Authors:  Hani S Mousa; Ana Lleo; Pietro Invernizzi; Christopher L Bowlus; Merril Eric Gershwin
Journal:  Expert Opin Pharmacother       Date:  2014-12-29       Impact factor: 3.889

7.  Structural basis and molecular mechanism of biased GPBAR signaling in regulating NSCLC cell growth via YAP activity.

Authors:  Lijuan Ma; Fan Yang; Xiang Wu; Chunyou Mao; Lulu Guo; Tianshu Miao; Shao-Kun Zang; Xiaoyu Jiang; Dan-Dan Shen; Tianhui Wei; Hengxing Zhou; Qin Wei; Shiyang Li; Qiang Shu; Shiqing Feng; Changtao Jiang; Bo Chu; Lutao Du; Jin-Peng Sun; Xiao Yu; Yan Zhang; Pengju Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-15       Impact factor: 12.779

8.  Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Cunbao Li; Cong Guo; Yanyan Li; Hui Qi; Hailing Shen; Jing Kong; Xuecheng Long; Frank Yuan; Xichun Wang; Wendong Huang
Journal:  Mol Endocrinol       Date:  2014-12-12

9.  Bile Acid Receptors and Liver Cancer.

Authors:  Xichun Wang; Xianghui Fu; Carl Van Ness; Zhipeng Meng; Xiaoxiao Ma; Wendong Huang
Journal:  Curr Pathobiol Rep       Date:  2012-12-21

Review 10.  Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer.

Authors:  Abigale Lade; Luke A Noon; Scott L Friedman
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.